Arno Therapeutics, Inc: 10-Q/A filed 2012-09-07

Name: Arno Therapeutics, Inc: 10-Q/A filed 2012-09-07
Creator: Arno Therapeutics, Inc

What Arno Therapeutics, Inc reported in its quarterly report amendment filed 2012-09-07 (fiscal Q2 2012): 27 published measures, 90 facts as tagged in accession 0001144204-12-050076.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form: 10-Q/A (quarterly report amendment)
Filed: 2012-09-07
Fiscal period: fiscal Q2 2012
Accession: 0001144204-12-050076 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Arno Therapeutics, Inc filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-06-30	2,224,917	USD
At 2011-12-31	7,024,420	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2012-06-30	3,323,117	USD
At 2011-12-31	5,668,781	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2012-06-30	-1,098,200	USD
At 2011-12-31	1,355,639	USD
At 2010-12-31	8,435,820	USD
At 2009-12-31	1,575,751	USD
At 2008-12-31	7,862,408	USD
At 2007-12-31	-3,627,590	USD
At 2006-12-31	-356,193	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-06-30	2,055,902	USD
At 2011-12-31	6,678,344	USD
At 2011-06-30	10,359,852	USD
At 2010-12-31	13,528,444	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	-275,306	USD	91
2012-01-01 to 2012-06-30	-2,843,937	USD	182
2005-08-01 to 2012-06-30	-38,356,937	USD	2526
2011-01-01 to 2011-12-31	-7,909,113	USD	365
2011-04-01 to 2011-06-30	-1,781,340	USD	91
2011-01-01 to 2011-06-30	-4,052,151	USD	181
2010-01-01 to 2010-12-31	-4,023,026	USD	365
2009-01-01 to 2009-12-31	-6,936,705	USD	365
2008-01-01 to 2008-12-31	-12,913,566	USD	366
2007-01-01 to 2007-12-31	-3,359,697	USD	365
2005-08-01 to 2006-12-31	-370,893	USD	518

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	-4,622,442	USD	182
2005-08-01 to 2012-06-30	-33,359,146	USD	2526
2011-01-01 to 2011-06-30	-3,162,076	USD	181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2005-08-01 to 2012-06-30	100,174	USD	2526
2011-01-01 to 2011-06-30	6,516	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2005-08-01 to 2012-06-30	35,600,347	USD	2526

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2005-08-01 to 2012-06-30	-185,299	USD	2526
2011-01-01 to 2011-06-30	-6,516	USD	181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2012-06-30	31,757	USD
At 2011-12-31	38,673	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	361,598	USD	182
2005-08-01 to 2012-06-30	3,310,002	USD	2526
2011-01-01 to 2011-06-30	235,642	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	-2,877,805	USD	91
2012-01-01 to 2012-06-30	-5,372,866	USD	182
2005-08-01 to 2012-06-30	-40,724,885	USD	2526
2011-04-01 to 2011-06-30	-1,857,328	USD	91
2011-01-01 to 2011-06-30	-3,467,455	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-06-30	2,182,705	USD
At 2011-12-31	6,975,292	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2005-08-01 to 2012-06-30	1,260,099	USD	2526

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-06-30	2,139,687	USD
At 2011-12-31	1,963,309	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-06-30	722,338	USD
At 2011-12-31	683,161	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	2,877,805	USD	91
2012-01-01 to 2012-06-30	5,372,866	USD	182
2005-08-01 to 2012-06-30	40,724,885	USD	2526
2011-04-01 to 2011-06-30	1,857,328	USD	91
2011-01-01 to 2011-06-30	3,467,455	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	2,341,092	USD	91
2012-01-01 to 2012-06-30	4,218,685	USD	182
2005-08-01 to 2012-06-30	32,526,763	USD	2526
2011-04-01 to 2011-06-30	1,309,776	USD	91
2011-01-01 to 2011-06-30	2,576,806	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-06-30	36,334,942	shares
At 2011-12-31	36,304,942	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-06-30	37,255,129	USD
At 2011-12-31	36,865,034	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2012-06-30	126,803	USD
At 2011-12-31	296,948	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	-275,306	USD	91
2012-01-01 to 2012-06-30	-2,843,937	USD	182
2011-04-01 to 2011-06-30	-1,781,340	USD	91
2011-01-01 to 2011-06-30	-4,133,802	USD	181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	536,713	USD	91
2012-01-01 to 2012-06-30	1,154,181	USD	182
2005-08-01 to 2012-06-30	8,198,122	USD	2526
2011-04-01 to 2011-06-30	547,552	USD	91
2011-01-01 to 2011-06-30	890,649	USD	181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	2,600,647	USD	91
2012-01-01 to 2012-06-30	2,523,689	USD	182
2005-08-01 to 2012-06-30	3,216,536	USD	2526
2011-04-01 to 2011-06-30	67,817	USD	91
2011-01-01 to 2011-06-30	-602,119	USD	181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	2,602,499	USD	91
2012-01-01 to 2012-06-30	2,528,929	USD	182
2005-08-01 to 2012-06-30	2,367,948	USD	2526
2011-04-01 to 2011-06-30	75,988	USD	91
2011-01-01 to 2011-06-30	-584,696	USD	181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2005-08-01 to 2012-06-30	17,690,037	USD	2526

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	59,177	USD	182
2005-08-01 to 2012-06-30	742,338	USD	2526
2011-01-01 to 2011-06-30	359,823	USD	181

Inspect the source

Entity: Arno Therapeutics, Inc / CIK 0001195116
Captured: 2026-09-23 02:48 UTC
SEC response SHA-256: daf59b1b66be981617a28a70398e42d86562bef04d5c645d4ccff16477481049

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001195116.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))